Semnur Registers 203.7M Shares Post-Merger, Warrants to Trade

TL;DR

**Semnur's S-1/A is a massive share dump by insiders, signaling potential dilution and price pressure for SMNRW.**

AI Summary

Semnur Pharmaceuticals, Inc. (SMNRW) filed an S-1/A on December 19, 2025, primarily for the registration of up to 203,737,349 shares of Common Stock and up to 8,760,000 shares issuable upon warrant exercise, along with 510,000 Private Warrants. The company will not receive proceeds from the resale of these shares or warrants, but will receive proceeds from the exercise of any Private Warrants and Public Warrants. The filing details the consummation of a Business Combination on September 22, 2025, with Legacy Semnur, formerly Denali Capital Acquisition Corp. The Common Stock and Public Warrants trade on the Pink Limited Market under symbols "SMNR" and "SMNRW" respectively, with a last reported sales price of $20.00 for Common Stock and $0.15 for Public Warrants on December 17, 2025. Key selling stockholders include Scilex Holding Company with up to 188,554,849 shares and Biconomy PTE.LTD with up to 12,500,000 shares. The company is an "emerging growth company" and has elected to comply with reduced reporting requirements.

Why It Matters

This S-1/A filing is crucial for investors as it facilitates the liquidity of a substantial number of shares and warrants following Semnur's Business Combination with Legacy Semnur on September 22, 2025. While Semnur won't directly benefit from the resale of these shares, the exercise of warrants could provide capital. The competitive landscape for emerging growth companies like Semnur, especially in the biotechnology sector, is intense, and the ability of major holders like Scilex and Biconomy to sell shares could impact market dynamics and valuation. Employees and customers will watch for how this capital structure impacts future R&D and operational stability.

Risk Assessment

Risk Level: high — The risk level is high due to the substantial number of shares being registered for resale (up to 203,737,349 shares of Common Stock) by Selling Stockholders, including 188,554,849 shares from Scilex Holding Company. This large potential supply of shares, coupled with the company not receiving proceeds from these resales, creates significant downward pressure on the stock price. Additionally, the Public Warrants trading at $0.15 on December 17, 2025, compared to the Common Stock at $20.00, suggests a high degree of uncertainty regarding future stock performance and warrant exercise.

Analyst Insight

Investors should exercise extreme caution and consider the significant potential for dilution from the 203,737,349 shares registered for resale. Current shareholders might consider reducing their exposure given the impending supply, while prospective investors should await a clearer picture of market absorption and the company's financial performance post-Business Combination.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $20.00 — Common Stock Price (Last reported sales price per share on December 17, 2025)
• $0.15 — Public Warrant Price (Last reported sales price per warrant on December 17, 2025)
• 203,737,349 — Shares for Resale (Maximum aggregate shares of Common Stock offered by Selling Stockholders)
• 8,760,000 — Shares Issuable from Warrants (Maximum aggregate shares of Common Stock issuable upon exercise of Warrants)
• 510,000 — Private Warrants (Number of Private Warrants offered by Selling Warrantholders)
• 188,554,849 — Scilex Shares (Shares of Common Stock held by Scilex Holding Company for resale)
• 12,500,000 — Biconomy Resale Shares (Shares of Common Stock held by Biconomy PTE.LTD for resale)
• September 22, 2025 — Business Combination Date (Date of consummation of the merger with Legacy Semnur)
• 8,250,000 — Public Warrants (Number of Public Warrants originally sold to public investors)
• $0.0001 — Common Stock Par Value (Par value per share of Semnur's Common Stock)

Key Players & Entities

• Semnur Pharmaceuticals, Inc. (company) — Registrant and issuer of securities
• Denali Capital Acquisition Corp. (company) — Pre-Business Combination name of Semnur Pharmaceuticals, Inc.
• Scilex Holding Company (company) — Selling Stockholder of up to 188,554,849 shares of Common Stock
• Biconomy PTE.LTD (company) — Selling Stockholder of up to 12,500,000 shares of Common Stock
• Jaisim Shah (person) — Chief Executive Officer of Semnur Pharmaceuticals, Inc.
• U.S. Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing
• Paul Hastings LLP (company) — Legal counsel for Semnur Pharmaceuticals, Inc.
• VStock Transfer, LLC (company) — Warrant agent for Public Warrants
• US Tiger Securities, Inc. (company) — Underwriter of Denali's IPO, party to Deferred Discount Agreement
• D. Boral Capital, LLC (company) — Underwriter of Denali's IPO, party to Deferred Discount Agreement

FAQ

Risk Factors

• Dependence on Key Personnel [high — operational]: The company's success is heavily reliant on its key management personnel, including its scientific and technical teams. The loss of any of these individuals could significantly disrupt operations and hinder the development and commercialization of its product candidates.
• Regulatory Approval Process [high — regulatory]: The pharmaceutical industry is subject to stringent regulatory oversight from bodies like the FDA. Obtaining approval for new drugs is a lengthy, expensive, and uncertain process. Delays or failures in obtaining regulatory approval for Semnur's product candidates would materially impact its ability to generate revenue.
• Need for Additional Funding [high — financial]: Semnur Pharmaceuticals has a history of operating losses and expects to incur significant expenses in the future as it advances its product candidates through clinical trials and seeks regulatory approval. The company may require substantial additional capital to fund its operations and development activities, and there is no guarantee that such funding will be available on acceptable terms.
• Competition in the Pharmaceutical Market [medium — market]: The pharmaceutical market is highly competitive, with numerous established companies and emerging biotechs developing therapies for similar indications. Semnur faces competition from companies with greater financial resources and established market presence, which could impact its ability to gain market share.
• Intellectual Property Risks [medium — legal]: The company's ability to protect its intellectual property (IP) is critical. Competitors may challenge its patents, or it may infringe on existing patents. Litigation related to IP could be costly and divert management attention.
• Manufacturing and Supply Chain Risks [medium — operational]: Scaling up manufacturing processes for pharmaceutical products can be complex and costly. Any disruptions in the supply chain or issues with manufacturing quality could lead to product shortages or recalls, impacting revenue and reputation.

Industry Context

Semnur Pharmaceuticals operates within the highly competitive and regulated biotechnology and pharmaceutical sector. The industry is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success often depends on innovation, intellectual property protection, and the ability to navigate complex clinical trial and approval processes.

Regulatory Implications

As a pharmaceutical company, Semnur is subject to rigorous oversight by regulatory bodies such as the FDA. The S-1/A filing itself is a regulatory requirement for registering securities. Failure to comply with FDA regulations regarding drug development, manufacturing, and marketing can lead to severe penalties, product recalls, and significant financial and reputational damage.

What Investors Should Do

1. Monitor Selling Stockholder Activity
2. Assess Warrant Value and Dilution
3. Evaluate Clinical Trial Progress and Regulatory Filings
4. Scrutinize Financial Health and Funding Needs

Key Dates

• 2025-09-22: Business Combination Consummation — Marks the completion of the merger between Semnur Pharmaceuticals and Denali Capital Acquisition Corp., leading to the current corporate structure and public trading.
• 2025-12-19: S-1/A Filing — Registration statement filed to allow for the resale of a significant number of shares and warrants by selling stockholders, indicating potential future selling pressure.
• 2025-12-17: Last Reported Sales Prices — Provides current market valuation context for Common Stock ($20.00) and Public Warrants ($0.15), highlighting the low current trading price of warrants.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC. It's used to update or correct information previously filed. (This filing is crucial for understanding the current share structure and the potential for future share dilution from selling stockholders.)

Emerging Growth Company

A company that has total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year. They are eligible for reduced reporting requirements. (Semnur Pharmaceuticals is utilizing these reduced requirements, meaning less detailed financial and operational information may be publicly available compared to larger, more established companies.)

Business Combination

A merger, acquisition, or other transaction that combines two or more companies. (This filing details the consummation of such a combination, which is a significant event that changes the company's structure and operations.)

Selling Stockholders

Existing shareholders who are registering their shares for resale to the public. (The large number of shares being registered by selling stockholders, particularly Scilex Holding Company, suggests potential for significant selling pressure in the market.)

Warrants

Securities that give the holder the right, but not the obligation, to purchase a company's stock at a specific price (the exercise price) before a certain expiration date. (The filing covers shares issuable upon warrant exercise, and the low trading price of public warrants ($0.15) suggests they are out-of-the-money or have low implied value.)

Pink Limited Market

A quotation venue for over-the-counter (OTC) securities that have less stringent listing requirements than major exchanges like Nasdaq or NYSE. (Trading on this market suggests lower liquidity and potentially higher volatility for SMNR and SMNRW compared to stocks listed on major exchanges.)

Year-Over-Year Comparison

This S-1/A filing follows the consummation of a business combination on September 22, 2025. As this is the initial detailed filing post-combination for resale purposes, direct year-over-year comparisons of key financial metrics like revenue, net income, or margins are not applicable within this document. The primary focus is on the registration of shares for resale and the potential market impact from selling stockholders, rather than historical financial performance trends.

Key Financial Figures

• $0.0001 — 0 shares of our common stock, par value $0.0001 per share ("Common Stock"), issuable up
• $20.00 — price per share of our Common Stock was $20.00. On December 17, 2025, the last reporte
• $0.15 — per warrant of our Public Warrants was $0.15. We are an "emerging growth company"
• $11.50 — one share of Common Stock at a price of $11.50 per share. " Registration Rights Agre
• $2,000,000 — ponsor in the total principal amount of $2,000,000, which bore interest equivalent to the
• $10.00 — rdinary Shares at a conversion price of $10.00 per ordinary share. " Sponsor Extensi

Filing Documents

• d63562ds1a.htm (S-1/A) — 3074KB
• d63562dex231.htm (EX-23.1) — 6KB
• g63562g00z31.jpg (GRAPHIC) — 116KB
• g63562g1018002926517.jpg (GRAPHIC) — 3KB
• g63562g1018002926773.jpg (GRAPHIC) — 5KB
• 0001193125-25-326813.txt ( ) — 9244KB
• smnr-20250630.xsd (EX-101.SCH) — 1104KB
• d63562ds1a_htm.xml (XML) — 1277KB

USE OF PROCEEDS

USE OF PROCEEDS 91 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES 92

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 100

BUSINESS

BUSINESS 112 EXECUTIVE AND DIRECTOR COMPENSATION 153 DIRECTORS AND EXECUTIVE OFFICERS 161

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 174 SELLING SECURITYHOLDERS 176 PLAN OF DISTRIBUTION 178

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 182 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 194 LEGAL MATTERS 201 EXPERTS 201 TRANSFER AGENT AND REGISTRAR 202 WHERE YOU CAN FIND MORE INFORMATION 202 INDEX TO FINANCIAL STATEMENTS F-1 i Table of Contents ABOUT THIS PROSPECTUS This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the "SEC") using the "shelf" registration process. Under this shelf registration process, the Selling Securityholders may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such Selling Securityholders of the securities offered by them described in this prospectus. This prospectus also relates to the issuance by us of the shares of Common Stock issuable upon the exercise of the Warrants. We will not receive any proceeds from the sale of shares of Common Stock underlying the Warrants pursuant to this prospectus, except with respect to amounts received by us upon the exercise of the Warrants for cash. Neither we nor the Selling Securityholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the Selling Securityholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the Selling Securityholders will make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable

View Full Filing

View this S-1/A filing on SEC EDGAR